Investor Presentaiton
US Formulations business
Consolidating the position amidst challenging environment
14,876
US Formulations Sales
(Rs. mn)
14,892
14,233
Q4 FY22 Revenue
Contribution
US Formulations Sales
(Rs. mn)
"
63,505
58,138
38%
$ 204
mn
$ 199
mn
$ 189
mn
$ 856
$ 780
◉
mn
mn
Q4FY21
Q3FY22
Q4FY22
FY21
FY22
YOY
-4.3%
Q4 FY22 Gr.
FY22 Gr.
-8.5%
QoQ
-4.4%
Continued investment to build the generics pipeline
ANDAS
Q4 FY22
FY22
Cumulative
Filings
1
26
420
Approvals
5
28
312
^
inclusive of 10 tentative approvals.
zydus
Dedicated To Life
Highlights for the quarter
Maintained top 3 ranking in 60% of the product
families in the US.
Received final approval for 5 new products and
launched 4 new products during the quarter.
On the Specialty front, acquired NULIBRY™
(Fosdenopterin for Injection).
The product is approved by the USFDA to reduce the
risk of mortality in patients with molybdenum cofactor
deficiency (MOCD) Type A, an ultra-rare, life-
threatening pediatric genetic disorder.
8View entire presentation